Form 4: Director David Goodman Reports Stock Transaction in NeuroMetrix, Inc.

Director David Goodman reports the vesting and conversion of restricted stock units into common stock of NeuroMetrix, Inc. on April 30, 2024.

Summary

• On April 30, 2024, Director David Goodman executed a transaction involving NeuroMetrix, Inc. (NURO) securities.
• Goodman converted 5,396 restricted stock units into common stock at a price of $4.37 per share.
• Following the transaction, Goodman directly owns 7,602 shares of NeuroMetrix, Inc. common stock.
• The restricted stock units, granted on August 4, 2023, vested fully on April 30, 2024.
• The original grant was for 43,165 restricted stock units before a 1-for-8 reverse stock split effective November 21, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard reporting of stock transactions related to vested equity compensation.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• Companies like Medtronic, Boston Scientific, and Abbott also have directors and officers who regularly file Form 4s when they trade company stock.
• The reporting requirements are consistent across the industry, as mandated by the SEC.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders as it is a routine vesting of equity compensation.
• It provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, Beneficial Ownership, NeuroMetrix, NURO, David Goodman, Restricted Stock Units, Stock Transaction, Director